Ibrutumomab tiuxetan is an adduct of a murine monoclonal antibody ibrutumomab which targets the B-cell CD20 surface antigen (present on most non-Hodgkins Lymphoma tumor cells) and the linker-chelator tiuxetan for binding the radioisotopes Indium-111 or Yttrium-90. Ibrutumomab tiuxetan has received regulatory approval in the US and Europe for the radioimmunotherapy (RIT) of CD20 positive, relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma. Indications include patients with rituximab refractory follicular non-Hodgkin’s lymphoma, used in combination with rituximab.
murine IgG1κ monoclonal antibody, conjugated to a chelator (tiuxetan) for labeling with Indium-111 or Yttrium-90
non-Hodgkins Lymphoma (CD20 positive, low-grade or follicular) which is relapsed or refractory to rituximab, in combination with rituximab
| Source | Link | Revision Date | Access Date |
| Zevalin Prescribing Information | http://www.zevalin.com/HealthCarePro...lthCarePro.htm | 2008-March | 2008-June-03 |
| Emmanouilides C. Radioimmunotherapy for non-hodgkin lymphoma : historical perspective and current status. J Clin Exp Hematop. 2007 Nov;47(2):43-60. Review | http://www.jstage.jst.go.jp/article/...47_43/_article | 2008-June-03 | |
| Witzig TE, Flinn IW, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002 Aug 1;20(15):3262-9 | http://www.ncbi.nlm.nih.gov/pubmed/12149300 | 2008-June-03 | |
| Witzig TE, Molina A, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 May 1;109(9):1804-10 | http://www3.interscience.wiley.com/c...6800/HTMLSTART | 2008-June-03 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
